HOME >> BIOLOGY >> NEWS
Molecular therapeutics advance fight against brain cancer

less responsive to chemotherapy, so radiation therapy is required sooner. "Given the expected increase in the life-span of patients with this deletion, there is no need to give radiation therapy early in their treatment," explains O'Rourke.

The deletion can only be detected by genetic analysis. "Under the microscope these tumors can look identical, so there's no way of knowing the difference unless a genetic analysis is performed," explains O'Rourke.

Having the ability to provide such genetic testing to determine treatment is of benefit to patients. "The idea of using a genetic test to predict prognosis and select therapy, thereby deferring potentially deleterious treatment is tremendously attractive," says O'Rourke. "Penn's genetic testing is done in-house, so patients don't have to wait for the results." Further, there is no cost to the patient at this point since the tests are performed by the Neuro-oncology Program and supported by the Abramson Cancer Center at Penn. In addition, there is no requirement for additional blood samples, so results will be given more quickly with no need for follow-up visits.

Penn colleagues J. Carl Oberholtzer, MD, PhD, Department of Neuropathology and Myrna Rosenfeld, MD, PhD, Department of Neurology and Director of the Division of Neuro-oncology as well as Jaclyn Biegel, PhD, Director of Cytogenetics, Children's Hospital of Philadelphia, collaborated with O'Rourke on developing the genetic testing program. Dr. Biegel's laboratory performs the genetic test and has significant experience with genetic testing of brain tumors.

O'Rourke is also Director of the Human Brain Tumor Tissue Bank at Penn, one of only a few such dedicated banks in the United States. Tissue banks allow for the direct evaluation of human tumors and are one of the best ways to advance treatment options for gliomas and other human cancers. O'Rourke's basic research interests include finding new treatments for gliomas based on ge
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
4-Aug-2004


Page: 1 2 3

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular motor shuttles key protein in response to light
7. Molecular traffic cop directs cellular signals
8. Molecular marker predicts success of breast cancer treatment
9. Molecular image of genotoxin reveals how bacteria damage human DNA
10. Molecular mechanism found that may improve ability of stem cells to fight disease
11. Molecular midwives hold clues to the origin of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2019)... ... 2019 , ... In the wake of the success of ... Chinese biobanks was launched in July 2018, in an agreement between IBBL, the ... Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered two testing schemes: ‘DNA ...
(Date:3/27/2019)... , ... March 27, 2019 , ... ... company has been awarded the 2019 Global Health & Pharma Biotechnology Award as ... Global Health & Pharma’s Biotechnology Awards honor individuals and companies whose accomplishments have ...
(Date:3/25/2019)... WHITEHOUSE, N.J. (PRWEB) , ... March 25, 2019 ... ... and tools, and Visikol, a contract research organisation focused on advancing drug discovery, ... clearing and 3D imaging. , Tissue clearing methods, which are essential to get ...
Breaking Biology News(10 mins):
(Date:4/15/2019)... (PRWEB) , ... April 15, 2019 , ... ... has completed construction of a $2 million bench plant expansion to increase production ... important step in the design and construction of Sirrus’ full-scale production facility, which ...
(Date:4/9/2019)... ... April 09, 2019 , ... ... increasing the capacity of life sciences organizations to accelerate innovation and maximize productivity, ... in the past 12 months. , USDM’s Cloud Assurance is ...
(Date:4/8/2019)... , ... April 08, 2019 , ... US Capital ... a $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma ... drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
Breaking Biology Technology:
Cached News: